文献速递炎症性肠病

营养不良与营养支持对住院炎症性肠病患者的影响

Impact of malnutrition and nutrition support in hospitalised patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-13

该观察性研究利用2010至2018年全国再入院数据库,分析住院炎症性肠病(IBD)与非IBD患者中蛋白质-热量营养不良(PCM)的趋势,以及营养不良和营养支持与再入院、死亡率、住院时长和费用的关联。结果显示IBD患者PCM风险为非IBD患者的2.9至3.1倍,PCM与再入院和死亡风险升高、住院更长及费用更高相关;营养支持与再入院风险降低相关,但与死亡率升高、住院延长和费用增加相关。作者认为营养支持可能降低再入院风险,需进一步研究。

要点

  • 住院IBD患者发生PCM的风险为非IBD患者的2.9至3.1倍。
  • IBD合并PCM患者再入院和死亡风险更高,住院更长且费用更高。
  • 营养支持与再入院风险降低相关,但与死亡率升高、住院延长和费用增加相关。

核心结论

  • 住院IBD患者中营养不良仍是再入院、死亡率、住院时长和医疗费用的重要影响因素。
  • 为IBD患者提供营养支持可能降低再入院风险。
  • 需要进一步研究评估住院IBD患者营养支持的作用,以优化疾病和医疗结局。

研究设计与样本

  • 观察性研究,查询2010至2018年全国再入院数据库,纳入IBD和非IBD住院患者。
  • 在IBD合并PCM患者中识别接受营养支持者。
  • 采用多变量Cox比例风险模型和Kaplan-Meier分析评估PCM和营养支持与再入院及死亡率的关联。
  • 采用多元线性回归描述比较变量与住院时长(LOS)和总住院费用的关联。

主要发现

  • 研究纳入克罗恩病(CD)患者1,216,033例(1,820,023次住院),溃疡性结肠炎(UC)患者832,931例(1,089,853次住院),非IBD患者240,488,656例(321,220,427次住院)。
  • 住院IBD患者发生PCM的可能性为非IBD患者的2.9至3.1倍。
  • IBD合并PCM患者再入院和死亡风险更高,住院时长更长,住院费用更高。
  • 营养支持(肠外和肠内)与再入院风险降低相关,但与死亡率升高、住院时长延长和总住院费用增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究评估住院IBD患者营养支持的作用,以优化疾病和医疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malnutrition is prevalent in patients with inflammatory bowel disease (IBD) and has been associated with worse clinical outcomes. AIMS: This observational study examines trends in protein-calorie malnutrition (PCM) amongst hospitalised IBD and non-IBD patients, and the association between (1) malnutrition and (2) nutrition support and hospitalisation outcomes. METHODS: We queried the Nationwide Readmissions Database from 2010 to 2018 for hospitalisations with and without IBD. Amongst patients with IBD and concurrent PCM, we identified those who received nutrition support. Multivariable Cox proportional hazards and Kaplan-Meier analyses evaluated the associations between PCM and nutrition support and readmission and mortality. Multiple linear regression described the association between compared variables and length of stay (LOS) and total hospitalisation costs. RESULTS: This study included 1,216,033 patients (1,820,023 hospitalisations) with Crohn's disease (CD), 832,931 patients (1,089,853 hospitalizations) with ulcerative colitis (UC) and 240,488,656 patients (321,220,427 hospitalisations) without IBD. Admitted IBD patients were 2.9-3.1 times more likely to have PCM than non-IBD patients. IBD patients with PCM had a higher risk of readmission and mortality, as well as longer LOS and higher hospitalisation costs. Nutrition support (parenteral and enteral) was associated with a reduced risk of readmission, but higher mortality increased LOS and higher total hospitalisation costs. CONCLUSIONS: Malnutrition in hospitalised IBD patients remains an important contributor to readmission, mortality, LOS and healthcare costs. Providing nutrition support to IBD patients may reduce the risk of readmission. Further studies are needed to evaluate the role of nutrition support amongst hospitalised IBD patients to optimise disease and healthcare outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dua A, Corson M, Sauk JS, et al. Impact of malnutrition and nutrition support in hospitalised patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 36638118. doi:10.1111/apt.17389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。